_Human_Recombinant_Protein_1_SDS_4x3.jpg "AKT1-(T308A-S473A)_Human_Recombinant_Protein SDS_PAGE")
_HumanRecombinant_Protein_2_WB_2x5.jpg "AKT1 (T308A/S473A) Human Recombinant Protein Western Blot")
AKT1 mutant (T308A S473A) Human Recombinant Protein
$50.00 to US & $70.00 to Canada for most products. Final costs are calculated at checkout.
Background
AKT1 is a component of the PI-3 kinase pathway and is activated by phosphorylation at Ser 473 and Thr 308. AKT is a cytoplasmic protein also known as Protein Kinase B (PKB) and RAC (Related to A and C kinases). AKT is a key regulator of many signal transduction pathways, and it exhibits tight control over cell proliferation and cell viability. Overexpression or inappropriate activation of AKT is noted in many types of cancer. AKT mediates many of the downstream events of PI 3-kinase (a lipid kinase activated by growth factors, cytokines and insulin). PI 3-kinase recruits AKT to the membrane, where it is activated by PDK1 phosphorylation. Once phosphorylated, AKT dissociates from the membrane and phosphorylates targets in the cytoplasm and the cell nucleus. AKT has two main roles: (i) inhibition of apoptosis; (ii) promotion of proliferation. AKT1 mutant (T308 / S473A) recombinant protein is ideal for investigators involved in Cell Signaling, Neuroscience and Signal Transduction research.
Product Details
Target Details
Application Details
Cell Line Data
Formulation
Shipping & Handling
This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.
Human_Recombinant_Protein_1_SDS_4x3.jpg)